CARDIOSPEX(TM) LIQUID CKMB/LD-1 IMMUNOINHIBITION— 510(k) K946146
Substantially EquivalentClinical Controls, Inc.
FDA 510(k) clearance K946146 for CARDIOSPEX(TM) LIQUID CKMB/LD-1 IMMUNOINHIBITION, Substantially Equivalent on 1995-01-24. Applicant: Clinical Controls, Inc.. Device class: 1.
Clearance details
- Applicant
- Clinical Controls, Inc.
- Product code
- Code JJT
- Device class
- Class 1
- Regulation
- 21 CFR 862.1660
- Advisory panel
- Clinical Chemistry
- Date received
- Decision date
- Decision
- Substantially Equivalent
- Clearance type
- Traditional
- Location
- Grover Beach, CA, US
Recent devices under product code JJT
view all- K090940 — SPOTCHECK BLOOD SPOT CONTROL, ASSAYED
- K062751 — MODIFICATION TO QUANTIMETRIX CARDIASURE CARDIAC MARKER
- K030768 — CLINIQA LIQUID QC CARDIAC MARKER CONTROL LEVELS 1, 2 & 3, TRI-LEVEL
- K030102 — ADVIA CENTAUR AND ACS:180 LIQUID CARDIAC MARKERS 1, 2, 3
- K021498 — LIQUICHEK CARDIAC MARKERS CONTROL LT LEVEL 1, 2, 3, AND TRILEVEL
More clearances from Clinical Controls, Inc.
view all- K964278 — WHOLE BLOOD GLUCOSE CONTROL LEVEL 1,2,AND 3/WHOLE BLOOD GLUCOSE LINEARITY CONTROL-LEVEL1,2,3,4,5,AND 6
- K962432 — LIQUISPEX URINE (MICRO)ALBUMIN CONTROL
- K955690 — AQUEOUS ETHANOL/AMMONIA CONTROL LEVEL 1, 2, & 3
- K955691 — SERUM VOLATILES CONTROL LEVEL 1 & 2
- K946265 — FIBRINOGEN HIGH ABNORMAL CONTROL - LEVEL 3
Data sourced from openFDA. This site is unofficial and independent of the FDA.